Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $633000.0.

  • Seres Therapeutics' Change in Accured Expenses rose 10695.6% to $633000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 14760.33%. This contributed to the annual value of -$10.2 million for FY2024, which is 16437.68% down from last year.
  • Latest data reveals that Seres Therapeutics reported Change in Accured Expenses of $633000.0 as of Q3 2025, which was up 10695.6% from -$352000.0 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Change in Accured Expenses ranged from a high of $38.6 million in Q3 2021 and a low of -$19.0 million during Q1 2023
  • Its 5-year average for Change in Accured Expenses is $2.5 million, with a median of $65000.0 in 2021.
  • As far as peak fluctuations go, Seres Therapeutics' Change in Accured Expenses skyrocketed by 649503.72% in 2023, and later plummeted by 75687.38% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Change in Accured Expenses stood at $65000.0 in 2021, then surged by 520.0% to $403000.0 in 2022, then surged by 6495.04% to $26.6 million in 2023, then plummeted by 126.12% to -$6.9 million in 2024, then skyrocketed by 109.12% to $633000.0 in 2025.
  • Its last three reported values are $633000.0 in Q3 2025, -$352000.0 for Q2 2025, and -$4.4 million during Q1 2025.